In the first study of three recurrent glioblastoma patients treated with CAR T-cell drugs, researchers discovered strong results, with one 72-year-old man’s brain tumor shrinking by 60% within two months.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
